Gumarontinib — Investigational Agent
Other · Phase 2 · Haihe Biopharma
Mechanism of Action
Highly selective, potent, ATP-competitive small-molecule MET (c-Met) kinase inhibitor targeting MET exon 14 skipping alterations and MET amplification, blocking HGF/MET-driven proliferation and survival signaling.
Investigational Indications
- MET exon 14 skipping NSCLC
- MET-amplified NSCLC
- MET-driven resistance after EGFR-TKI (with 3rd-gen EGFR-TKI)